BR112019007843A2 - métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) - Google Patents
métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)Info
- Publication number
- BR112019007843A2 BR112019007843A2 BR112019007843A BR112019007843A BR112019007843A2 BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2 BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- individual
- atherosclerotic cardiovascular
- pcsk9
- subtilisin
- Prior art date
Links
- 102000006437 Proprotein Convertases Human genes 0.000 title 1
- 108010044159 Proprotein Convertases Proteins 0.000 title 1
- 108090000787 Subtilisin Proteins 0.000 title 1
- 230000007211 cardiovascular event Effects 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
a presente invenção refere-se a um método de redução do colesterol de lipoproteína de baixa densidade ou prevenção de um evento cardíaco em um indivíduo que tem doença cardiovascular ate-rosclerótica ou equivalente de risco cardiovascular aterosclerótico, envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. igualmente, um método de prevenção do desenvolvimento de doença cardiovascular aterosclerótica em um indivíduo envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. além disso, um método de tratamento de um indivíduo que tem doença cardiovascular aterosclerótica ou que está em equivalente de risco da doença cardiovascular aterosclerótica envolvendo a administração ao indivíduo de uma quantidade terapeuticamente eficaz de um agente de rnai.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409816P | 2016-10-18 | 2016-10-18 | |
US201662422028P | 2016-11-14 | 2016-11-14 | |
US201762472525P | 2017-03-16 | 2017-03-16 | |
US201762550426P | 2017-08-25 | 2017-08-25 | |
PCT/US2017/057218 WO2018075658A1 (en) | 2016-10-18 | 2017-10-18 | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019007843A2 true BR112019007843A2 (pt) | 2019-10-01 |
Family
ID=60388127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019007843A BR112019007843A2 (pt) | 2016-10-18 | 2017-10-18 | métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) |
Country Status (15)
Country | Link |
---|---|
US (2) | US20180104360A1 (pt) |
EP (2) | EP4397311A2 (pt) |
JP (2) | JP7181881B2 (pt) |
KR (2) | KR20240067272A (pt) |
CN (1) | CN110088283A (pt) |
AU (2) | AU2017346879B2 (pt) |
BR (1) | BR112019007843A2 (pt) |
CA (1) | CA3042423A1 (pt) |
CL (1) | CL2019001047A1 (pt) |
DK (1) | DK3529360T3 (pt) |
FI (1) | FI3529360T3 (pt) |
IL (1) | IL266066A (pt) |
LT (1) | LT3529360T (pt) |
MX (1) | MX2019004573A (pt) |
WO (1) | WO2018075658A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114469984A (zh) | 2015-08-25 | 2022-05-13 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
AU2017346879B2 (en) | 2016-10-18 | 2023-11-30 | Novartis Ag | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction |
EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
JP7436030B2 (ja) | 2017-12-29 | 2024-02-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 複合体及びその調製方法と使用 |
CN111655849B (zh) | 2018-08-21 | 2024-05-10 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
US20230313195A1 (en) * | 2019-05-22 | 2023-10-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
WO2021185765A1 (en) | 2020-03-16 | 2021-09-23 | Argonaute RNA Limited | Antagonist of pcsk9 |
WO2024061157A1 (en) * | 2022-09-19 | 2024-03-28 | Kylonova (Xiamen) Biopharma Co., Ltd. | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101484588B (zh) * | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
JP6574383B2 (ja) * | 2012-12-05 | 2019-09-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | PCSK9iRNA組成物及びその使用方法 |
AU2017346879B2 (en) | 2016-10-18 | 2023-11-30 | Novartis Ag | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (PCSK9) protein reduction |
-
2017
- 2017-10-18 AU AU2017346879A patent/AU2017346879B2/en active Active
- 2017-10-18 JP JP2019542356A patent/JP7181881B2/ja active Active
- 2017-10-18 KR KR1020247014347A patent/KR20240067272A/ko active Search and Examination
- 2017-10-18 DK DK17800976.7T patent/DK3529360T3/da active
- 2017-10-18 US US15/787,405 patent/US20180104360A1/en not_active Abandoned
- 2017-10-18 BR BR112019007843A patent/BR112019007843A2/pt unknown
- 2017-10-18 LT LTEPPCT/US2017/057218T patent/LT3529360T/lt unknown
- 2017-10-18 EP EP24170268.7A patent/EP4397311A2/en active Pending
- 2017-10-18 WO PCT/US2017/057218 patent/WO2018075658A1/en active Application Filing
- 2017-10-18 CN CN201780077941.7A patent/CN110088283A/zh active Pending
- 2017-10-18 CA CA3042423A patent/CA3042423A1/en active Pending
- 2017-10-18 KR KR1020197014059A patent/KR20190077411A/ko not_active Application Discontinuation
- 2017-10-18 EP EP17800976.7A patent/EP3529360B1/en active Active
- 2017-10-18 MX MX2019004573A patent/MX2019004573A/es unknown
- 2017-10-18 FI FIEP17800976.7T patent/FI3529360T3/fi active
-
2019
- 2019-04-16 IL IL266066A patent/IL266066A/en unknown
- 2019-04-17 CL CL2019001047A patent/CL2019001047A1/es unknown
-
2020
- 2020-06-22 US US16/908,517 patent/US20210093736A1/en active Pending
-
2022
- 2022-04-19 JP JP2022068684A patent/JP2022109948A/ja active Pending
-
2023
- 2023-11-09 AU AU2023263519A patent/AU2023263519A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023263519A1 (en) | 2023-12-07 |
CA3042423A1 (en) | 2018-04-26 |
KR20190077411A (ko) | 2019-07-03 |
AU2017346879B2 (en) | 2023-11-30 |
WO2018075658A1 (en) | 2018-04-26 |
DK3529360T3 (da) | 2024-07-15 |
EP3529360B1 (en) | 2024-04-17 |
LT3529360T (lt) | 2024-07-25 |
US20210093736A1 (en) | 2021-04-01 |
JP2019531357A (ja) | 2019-10-31 |
FI3529360T3 (fi) | 2024-07-11 |
JP7181881B2 (ja) | 2022-12-01 |
CN110088283A (zh) | 2019-08-02 |
JP2022109948A (ja) | 2022-07-28 |
KR20240067272A (ko) | 2024-05-16 |
MX2019004573A (es) | 2019-10-07 |
EP3529360A1 (en) | 2019-08-28 |
CL2019001047A1 (es) | 2020-05-08 |
EP4397311A2 (en) | 2024-07-10 |
IL266066A (en) | 2019-06-30 |
AU2017346879A1 (en) | 2019-05-23 |
US20180104360A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019007843A2 (pt) | métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) | |
MY195432A (en) | Methods For Inhibiting Angiogenesis In A Subject In Need Thereof | |
CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
BR112015000174A2 (pt) | método para o tratamento da artrite | |
BR112015017101A2 (pt) | composições de tratamento compreendendo microcápsulas, aminas primárias ou secundárias e sequestrantes de formaldeído | |
BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
MX2017005030A (es) | Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. | |
BR112013028440A2 (pt) | composições e métodos que compreendem variantes de serina protease | |
BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
MX2014013523A (es) | Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos. | |
BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
BR112015000321A2 (pt) | formulações de laquinimod sem agente alcalinizante | |
BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
EA201791993A1 (ru) | Способы лечения протеинопатий | |
BR112018013833A2 (pt) | métodos de administração de hepcidina | |
PH12019500422A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112019009726A2 (pt) | terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica | |
BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
BR112014000773A8 (pt) | Composições de nicotinamida e uso terapêutico das mesmas | |
BR112014010594A2 (pt) | terapia genética para neuropatia diabética empregando um isoforma do hgf | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026853-6 PROTOCOLO 870220122961 EM 28/12/2022 14:30. |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |